Data too important to share: do those who control the data control the message?
PublisherBMJ Publishing Group
MetadataShow full item record
DescriptionHydroxyethyl starch solutions for fluid resuscitation fell from grace in 2013 after European and American regulators issued severe warnings about their safety. But the academic investigators that led a landmark trial that helped precipitate this downfall are refusing to share their data. Is this acceptable? Peter Doshi reports.
CitationDoshi, P. (2016). Data too important to share: do those who control the data control the message? BMJ 2016;352:i1027. DOI: https://doi.org/10.1136/bmj.i1027
Hydroxyethyl Starch Derivatives
Clinical Trials as Topic
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6602
- NHS should ban use of starch based intravenous fluids, say researchers.
- Authors: Wise J
- Issue date: 2013 Feb 27
- Update: New England Journal of Medicine publishes correction to 2012 CHEST trial of hydroxyethyl starch versus colloids.
- Authors: Doshi P
- Issue date: 2016 Mar 21
- Is fluid resuscitation with high-volume hydroxyethyl starch safe for the kidney in trauma patients?
- Authors: Xue FS, Liu GP, Li RP, Sun C
- Issue date: 2015 Aug
- Deleterious renal effects of hydroxyethyl starch 130/0.4 and 200/0.5 solutions.
- Authors: Davidson IJ
- Issue date: 2007 Oct
- Hydroxyethyl starch for resuscitation.
- Authors: Haase N, Perner A
- Issue date: 2013 Aug